Danone maintains guidance as Q2 sales top forecasts

• Specialised nutrition sales rose 4.5% and water business grew 4.7%, benefiting from hot European summer weather that boosted Volvic sales
• First-half recurring operating margin improved to 13.3% from 13.2% year-over-year, slightly above the 13.25% consensus, supported by strong productivity gains
• Volume growth of 1.9% was considered lacklustre by Bernstein analysts, who noted particular concerns about U.S. Essential Dairy Products performance

Danone Q2 2026 Results Summary

Key Performance Metrics:

Danone reported Q2 2026 like-for-like sales growth of 4.2%, surpassing analyst expectations of 3.7%. The company posted first-half recurring operating income of €1.854 billion ($2.11 billion) with a margin of 13.3%, up from 13.2% year-over-year and above the expected 13.25%. Price increases contributed 2.3% to growth, while volumes rose 1.9%.

Business Segment Performance:

The specialised nutrition division led growth with a 4.5% increase, recovering from a European baby formula recall and supply disruptions related to the Iran war. The water business grew 4.7%, benefiting from a hot European summer that boosted Volvic sales. Strong demand was noted for high-protein, medical nutrition, and plant-based products.

Company Brands:

Danone's portfolio includes Evian and Badoit water brands, along with Activia yoghurt.

Guidance and Outlook:

The French consumer goods group maintained its 2026 full-year guidance, targeting like-for-like sales growth of 3-5% with recurring operating income growing faster than sales. CEO Antoine de Saint-Affrique expressed confidence in the second half despite ongoing environmental instability and continued challenges in North American Essential Dairy Products.

Market Implications:

Bernstein analysts anticipated a "slightly mixed reception," expecting consensus estimates to rise 1-2 percentage points but raising concerns about lacklustre volume growth, particularly in U.S. Essential Dairy Products. The results demonstrate productivity gains offsetting pressures from the baby formula recall and early inflationary effects.